PainTEQ Enhances Its Leadership with Med-Tech Expert Robert Kline to Transform Spine Care

Enhancing Spine Care: Robert Kline Joins PainTEQ's Leadership

In a pivotal move, PainTEQ, a leader in med-tech solutions, has announced the appointment of Robert Kline to its Board of Directors. Kline's extensive experience in commercializing groundbreaking medical devices positions him uniquely to help drive the company’s mission to redefine interventional spine care. With over 25 years in the medical technology sector, Kline brings a wealth of knowledge and strategic insight that is expected to significantly impact PainTEQ’s growth trajectory.

Kline's previous roles include being the founder of Medivance, a pioneer in therapeutic temperature management that was acquired by C.R. Bard in 2011. He also co-founded ViroCyt, a technology firm that was absorbed by Sartorius AG in 2016. His tenure as CEO at Bolder Surgical, which was bought by Hologic, Inc. for a remarkable $160 million in 2021, is particularly noteworthy. Kline's track record exemplifies his ability to lead companies towards significant commercial success through innovation and market adaptation.

"PainTEQ has a clear and essential vision for the market," Kline stated regarding his new role. He expressed confidence in the company’s flagship LinQ system, highlighting that it not only delivers superior patient outcomes but does so in a highly efficient manner. His endorsement underscores the commitment to providing high-quality patient care while optimizing operational efficiencies.

Shanth Thiyagalingam, CEO of PainTEQ, voiced his enthusiasm for Kline's addition to the team. He emphasized that Kline’s strategic guidance would give PainTEQ a robust competitive edge in an ever-evolving market. As the company aims to expand its influence and enhance its offerings, having Kline on board will support the accelerated adoption and responsible expansion of the LinQ system.

The LinQ SI Joint Stabilization System, PainTEQ’s flagship product, has already seen significant success, with relief provided in over 14,000 procedures. Unlike conventional surgical interventions, LinQ's innovative single-implant, posterior approach ensures a lower risk profile, leading to quicker recovery times and reduced tissue damage. This is a transformative step for patients suffering from painful sacroiliac joint dysfunction, helping them return to their daily lives sooner and with less discomfort.

David Kereiakes, Managing Partner at Windham Capital Partners and a member of PainTEQ's board, commented on Kline’s leadership. He praised Kline's exceptional talent for driving results and speculated that his insights will prove invaluable in the medical technology landscape.

PainTEQ is dedicated to revolutionizing interventional procedures, focusing on cutting-edge solutions for pain management specialists. The LinQ implant and its associated single-use instruments not only aim to reduce SI joint dysfunction but also strive to deliver immediate clinical benefits via minimally invasive outpatient procedures. Interested readers can find more at PainTEQ's Website.

In summary, Robert Kline's integration into PainTEQ represents a significant strategic move for the company, one that promises to elevate their capabilities and further cement their role as leaders in the med-tech industry. Through innovation and evidence-based practice, PainTEQ is poised to continue making strides in the evolving landscape of spine care.